Holen Sie sich die Stockscreener-App
1.05
6.06%
0.06
Handel nachbörslich:
1.05
Palatin Technologies Inc. Aktie (PTN) Neueste Nachrichten
Palatin Technologies Inc [PTN] stock for 8,274 USD was sold by WILLS STEPHEN T - Knox Daily
Palatin Technologies prices 4.69M shares in direct offering - MSN
Palatin Gains on New Offering - Baystreet.ca
Palatin Technologies Announces $4.7 Mln Direct Offering - Nasdaq
Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement - Marketscreener.com
Palatin secures $4.7 million in stock and warrant sale - Investing.com
Palatin secures $4.7 million in stock and warrant sale By Investing.com - Investing.com UK
Palatin's Strategic $4.7M Healthcare Investment Deal: Inside the Critical Financing Terms - StockTitan
Palatin concludes Phase II trial of combination therapy for obesity - Clinical Trials Arena
As Saudi Arabia’s Tourism Sector Grows Exponentially, dmg events Announces Hotel & Hospitality Expo - GlobeNewswire Inc.
Palatin finishes phase 2 trial in obesity treatment study By Investing.com - Investing.com Nigeria
Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide - GuruFocus.com
Palatin finishes phase 2 trial in obesity treatment study - Investing.com
Obesity Treatment Breakthrough? Palatin's Novel GLP-1 Combo Trial Wraps Up With Massive Patient Interest - StockTitan
PTN’s price-to-sales ratio: A comparative analysis with its peers - US Post News
Palatin Technologies Inc (PTN) Stock: What the Analysts are Saying - The News Heater
PTN’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Market Watch: Palatin Technologies Inc (PTN)’s Noteworthy Drop, Closing at 0.80 - The Dwinnex
Palatin Technologies (NYSEAMERICAN:PTN) Earns “Buy” Rating from HC Wainwright - Defense World
Palatin gears up for obesity treatment trials in 2025 By Investing.com - Investing.com Canada
Palatin gears up for obesity treatment trials in 2025 - MSN
Palatin's Game-Changing Obesity Drug Strategy Takes Aim at 67% Treatment Dropout Rate - StockTitan
Palatin spikes as FDA clears mid-stage trial for weight loss therapy - MSN
Palatin starts Phase 2 obesity study of bremelanotide with Zepbound - MSN
HB Wealth Management LLC Has $127,000 Stock Position in Palatin Technologies, Inc. (NYSEAMERICAN:PTN) - Defense World
Palatin Technologies (NYSEAMERICAN:PTN) Shares Cross Above 200-Day Moving Average – What’s Next? - Defense World
Palatin Technologies Inc (AMEX: PTN) Analysts Expect It Could Climb 93.76% From Current Levels. - Stocks Register
FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivota - GuruFocus.com
Palatin reports positive Phase 2b results in diabetic nephropathy - Yahoo Finance
First Patient Dosed in Phase 2 Clinical Study of Palatin's Breme - GuruFocus.com
Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy - PR Newswire
Palatin Technologies announces warrant exercise for ~$3.4M gross proceeds - MSN
Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds - The Eastern Progress Online
Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results - The Eastern Progress Online
Palatin Technologies (BUE:PTN) Financial Strength : 4 (As of Sep. 2024) - GuruFocus.com
Thinking about buying stock in MedAvail Holdings, Trio-Tech Inte - GuruFocus.com
PTN (Palatin Technologies) Price-to-Free-Cash-Flow : N/A (As of Dec. 01, 2024) - GuruFocus.com
PTN (Palatin Technologies) COGS-to-Revenue : 0.00 (As of Sep. 2024) - GuruFocus.com
Palatin Technologies stock stays Buy rated after completing Phase 2 enrollment in UC trial - Investing.com UK
Palatin Announces Completion of Patient Enrollment in Phase 2 St - GuruFocus.com
Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis – Company AnnouncementFT.com - Financial Times
Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis - PR Newswire
Palatin Technologies (FRA:PTN) Retained Earnings : €-405.08 Mil (As of Sep. 2024) - GuruFocus.com
Palatin Technologies (FRA:PTN) Graham Number : €N/A (As of Sep. 2024) - GuruFocus.com
Palatin Technologies (FRA:PTN) Float Percentage Of Total Sh - GuruFocus.com
Palatin to Report First Quarter Fiscal Year 2025 Results; Teleco - GuruFocus.com
Palatin Technologies, Inc. (AMEX:PTN) Q1 2025 Earnings Call Transcript - Insider Monkey
Palatin Technologies Inc (PTN) Quarterly 10-Q Report - Quartzy
Palatin Technologies Inc (PTN) Q1 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue Challenges - GuruFocus.com
Palatin Technologies Inc (PTN) Q1 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue ... - Yahoo Finance
Palatin Technologies Inc (PTN) Q1 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue ... By GuruFocus - Investing.com Canada
1.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):